ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,08575
-0,03%
Bitcoin
70.177,95
-1,78%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Alvontech (ALVO)

  7. Alvontech (ALVO) News

ALVO

Alvontech (ALVO)

Alvontech
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ALVO
DatumZeitQuelleÜberschriftSymbolFirma
21/05/202423h15GlobeNewswire Inc.Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business UpdateNASDAQ:ALVOAlvontech
21/05/202416h05Business WireAlvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UKNASDAQ:ALVOAlvontech
21/05/202414h00GlobeNewswire Inc.Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKNASDAQ:ALVOAlvontech
21/05/202413h13IH Market NewsU.S. Index Futures Open Lower Amid Nasdaq Record, Fed SpeechesNASDAQ:ALVOAlvontech
21/05/202402h25Business WireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NASDAQ:ALVOAlvontech
21/05/202402h25GlobeNewswire Inc.Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NASDAQ:ALVOAlvontech
13/05/202414h00GlobeNewswire Inc.Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)NASDAQ:ALVOAlvontech
02/05/202413h15GlobeNewswire Inc.Alvotech Announces Participation at BofA Securities Healthcare Conference 2024NASDAQ:ALVOAlvontech
30/04/202410h00GlobeNewswire Inc.U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NASDAQ:ALVOAlvontech
30/04/202410h00Business WireU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NASDAQ:ALVOAlvontech
24/04/202410h00GlobeNewswire Inc.Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)NASDAQ:ALVOAlvontech
19/04/202412h10GlobeNewswire Inc.Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)NASDAQ:ALVOAlvontech
16/04/202423h43Business WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
16/04/202423h30GlobeNewswire Inc.Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
03/04/202413h41GlobeNewswire Inc.Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024NASDAQ:ALVOAlvontech
22/03/202421h15GlobeNewswire Inc.Alvotech Announces Increase in Number of Own SharesNASDAQ:ALVOAlvontech
20/03/202421h15GlobeNewswire Inc.Alvotech Reports Financial Results for Full Year 2023 and Provides a Business UpdateNASDAQ:ALVOAlvontech
20/03/202412h17IH Market NewsU.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices DipNASDAQ:ALVOAlvontech
05/03/202422h00GlobeNewswire Inc.Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ETNASDAQ:ALVOAlvontech
29/02/202422h05GlobeNewswire Inc.Alvotech Appoints Interim Chief Quality OfficerNASDAQ:ALVOAlvontech
26/02/202410h25GlobeNewswire Inc.Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per ShareNASDAQ:ALVOAlvontech
24/02/202402h15GlobeNewswire Inc.Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NASDAQ:ALVOAlvontech
24/02/202402h15Business WireAlvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NASDAQ:ALVOAlvontech
15/02/202412h30GlobeNewswire Inc.Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
29/01/202410h00GlobeNewswire Inc.Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®NASDAQ:ALVOAlvontech
19/01/202418h31Dow Jones NewsAlvotech Shares Climb After FDA Concludes Facility InspectionNASDAQ:ALVOAlvontech
19/01/202417h30GlobeNewswire Inc.Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04NASDAQ:ALVOAlvontech
10/01/202409h30GlobeNewswire Inc.STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to StelaraNASDAQ:ALVOAlvontech
03/01/202409h30GlobeNewswire Inc.Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)NASDAQ:ALVOAlvontech
29/11/202310h00GlobeNewswire Inc.Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®NASDAQ:ALVOAlvontech
 Showing the most relevant articles for your search:NASDAQ:ALVO

Kürzlich von Ihnen besucht

TG
TUI1
Tui
TG
ALV
Allianz
TG
BAS
BASF
DBI
DAX
DAX
CCOM
US500
US 500
TG
BAYN
Bayer
USOTC
ADDYY
Adidas (QX)
USOTC
BNPQY
BNP Paribas (QX)
TG
DBK
Deutsche Bank
CCOM
SILVER
SILVER
TG
CBK
Commerzbank
NASDAQ
NVDA
NVIDIA
NASDAQ
AMZN
Amazon.com
TG
MBG
MercedesBenz
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten